Mural Oncology Announces Number of Relevant Securities in Issue

Company Overview - Mural Oncology plc is a clinical-stage immuno-oncology company focused on developing cytokine-based immunotherapies for cancer treatment [4] - The company is headquartered in Dublin, Ireland, with primary facilities located in Waltham, Massachusetts [4] Share Capital and Securities - As of May 1, 2025, Mural's issued share capital consisted of 17,268,881 ordinary shares with a par value of US$0.01 each [1] - As of March 31, 2025, there were 1,121,460 non-vested restricted stock units and 3,725,736 options to purchase ordinary shares outstanding [2] Regulatory Compliance - The announcement is made in accordance with Rule 2.12 of the Irish Takeover Rules [1][4] - Under Rule 8.3(a), any person interested in 1% or more of Mural's relevant securities must make an opening position disclosure by the specified deadline [6] - Rule 8.3(b) requires disclosure of all dealings in relevant securities during the offer period for those interested in 1% or more [7]